Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Regulatory Agenda Includes “Complete Response” Rule, E-Drug Listing

Executive Summary

A notice of proposed rulemaking for FDA's "complete response" regulation is scheduled for publication in July, according to HHS' semiannual regulatory agenda published in the June 28 Federal Register
Advertisement

Related Content

FDA Investor Relations: SEC Agreement Close, “Complete Response” Reg Not
FDA Investor Relations: SEC Agreement Close, “Complete Response” Reg Not
FDA 2004 Reg Agenda Includes CFC Albuterol Phase Out, Final Label Rule
FDA Investigational Drug Export Rule Encourages IND, Requires Certification

Topics

Advertisement
UsernamePublicRestriction

Register

PS044282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel